دورية أكاديمية
أعرض في EDS

Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial.

التفاصيل البيبلوغرافية
العنوان: Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial.
المؤلفون: Ahmadi R; Department of Family Medicine School of Medicine Mashhad University of Medical Sciences Mashhad Iran., Salari S; Department of Clinical Pharmacy School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran., Sharifi MD; Faculty of Medicine Department of Emergency Medicine Mashhad University of Medical sciences Mashhad Iran.; Department of Internal Medicine Mashhad University of Medical Sciences Mashhad Iran., Reihani H; Faculty of Medicine Department of Emergency Medicine Mashhad University of Medical sciences Mashhad Iran.; Department of Internal Medicine Mashhad University of Medical Sciences Mashhad Iran., Rostamiani MB; Department of Clinical Pharmacy School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran., Behmadi M; Faculty of Medicine Department of Emergency Medicine Mashhad University of Medical sciences Mashhad Iran.; Department of Internal Medicine Mashhad University of Medical Sciences Mashhad Iran., Taherzadeh Z; Targeted Drug Delivery Research Center School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran., Eslami S; Faculty of Medicine Department of Medical Informatics Mashhad University of Medical Sciences Mashhad Iran., Rezayat SM; Department of Pharmacology School of Medicine Tehran University of Medical Sciences Tehran Iran., Jaafari MR; Nanotechnology Research Center Pharmaceutical Technology Institute Mashhad University of Medical Sciences Mashhad Iran.; Department of Pharmaceutical Nanotechnology School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran., Elyasi S; Department of Family Medicine School of Medicine Mashhad University of Medical Sciences Mashhad Iran.
المصدر: Food science & nutrition [Food Sci Nutr] 2021 Jun 19; Vol. 9 (8), pp. 4068-4075. Date of Electronic Publication: 2021 Jun 19 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101605473 Publication Model: eCollection Cited Medium: Print ISSN: 2048-7177 (Print) Linking ISSN: 20487177 NLM ISO Abbreviation: Food Sci Nutr Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Malden, MA : John Wiley & Sons, [2012]-
مستخلص: Background: Curcumin, a natural polyphenolic compound, is proposed as a potential treatment option for patients with coronavirus disease by inhibiting the entry of virus to the cell, encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. In this study, the efficacy and safety of nanocurcumin oral formulation has been evaluated in patients with mild-moderate Coronavirus disease 2019 (COVID-19) in outpatient setting.
Methods: In this triple-blind randomized placebo-controlled clinical trial, sixty mild to moderate COVID-19 patients in outpatient setting who fulfilled the inclusion criteria were randomly allocated to treatment ( n  = 30) group to receive oral nanocurcumin formulation (Sinacurcumin soft gel which contains 40 mg curcuminoids as nanomicelles), two soft gels twice a day after food for 2 weeks or placebo ( n  = 30) group. Patients' symptoms and laboratory data were assessed at baseline and during follow-up period and compared between two groups.
Results: All symptoms except sore throat resolved faster in the treatment group and the difference was significant for chills, cough and smell and taste disturbances. The CRP serum level was lower in the treatment group at the end of two weeks and the lymphocyte count was significantly higher in treatment group. No significant adverse reaction reported in the treatment group.
Conclusion: Oral nanoformulation of curcumin can significantly improve recovery time in patients with mild to moderate COVID-19 in outpatient setting. Further studies with larger sample size are recommended.
Competing Interests: Dr Mahmoud Reza Jaafari, one of the manuscript authors, is the founder of Exir Nano Sina Company. Other authors have nothing to declare. The study conforms to the Declaration of Helsinki, US, and/or European Medicines Agency Guidelines for human subjects.
(© 2021 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.)
References: J Biol Chem. 1995 Oct 20;270(42):24995-5000. (PMID: 7559628)
Phytother Res. 2020 Nov;34(11):2911-2920. (PMID: 32430996)
Lancet. 2020 Feb 15;395(10223):e30-e31. (PMID: 32032529)
Circulation. 2009 Jun 16;119(23):3028-35. (PMID: 19528344)
Food Chem Toxicol. 2020 Nov;145:111699. (PMID: 32858134)
J Cell Physiol. 2021 Jul;236(7):5325-5338. (PMID: 33372280)
Phytother Res. 2020 Sep;34(9):2085-2087. (PMID: 32442323)
Adv Exp Med Biol. 2007;595:213-26. (PMID: 17569213)
Expert Opin Drug Metab Toxicol. 2019 Sep;15(9):705-733. (PMID: 31361978)
Lancet. 2020 Mar 28;395(10229):1033-1034. (PMID: 32192578)
Stat Methods Med Res. 2016 Jun;25(3):1057-73. (PMID: 26092476)
Phytother Res. 2021 May;35(5):2616-2623. (PMID: 33389761)
JAMA. 2020 Apr 28;323(16):1574-1581. (PMID: 32250385)
Phytother Res. 2020 Oct;34(10):2425-2428. (PMID: 32488956)
Int Immunopharmacol. 2020 Dec;89(Pt B):107088. (PMID: 33129099)
Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577. (PMID: 27761427)
J Pharmacol Exp Ther. 2016 Jun;357(3):620-8. (PMID: 27000801)
Nutrition. 2009 Feb;25(2):125-9. (PMID: 19028079)
Travel Med Infect Dis. 2020 Mar - Apr;34:101623. (PMID: 32179124)
Chest. 2007 Oct;132(4):1311-21. (PMID: 17934117)
Respir Res. 2019 Jun 6;20(1):110. (PMID: 31170972)
J Clin Psychopharmacol. 2016 Jun;36(3):236-43. (PMID: 27043120)
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193)
Curr Rheumatol Rev. 2020;16(2):158-164. (PMID: 31868149)
Iran J Basic Med Sci. 2019 Mar;22(3):282-289. (PMID: 31156789)
Neurotherapeutics. 2018 Apr;15(2):430-438. (PMID: 29352425)
Biomed Res Int. 2014;2014:186864. (PMID: 24877064)
Food Sci Nutr. 2020 Sep 06;8(10):5215-5227. (PMID: 33133525)
JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524)
Food Sci Nutr. 2021 Jun 19;9(8):4068-4075. (PMID: 34401058)
Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32661006)
Molecules. 2020 Feb 06;25(3):. (PMID: 32041140)
فهرسة مساهمة: Keywords: COVID‐19; Curcumin; anti‐inflammatory; clinical response
تواريخ الأحداث: Date Created: 20210817 Latest Revision: 20240403
رمز التحديث: 20240403
مُعرف محوري في PubMed: PMC8358331
DOI: 10.1002/fsn3.2226
PMID: 34401058
قاعدة البيانات: MEDLINE
الوصف
تدمد:2048-7177
DOI:10.1002/fsn3.2226